Skip to main content
. 2022 Jun 6;10(3):e02684-21. doi: 10.1128/spectrum.02684-21

TABLE 3.

Proportion of individuals achieving ganciclovir therapeutic AUC24 values between the study cohort and simulation to match the manufacturer’s dosing guidelines

Regimen % of subjects achieving therapeutic AUC24
<40 μg·h/mL 40–50 μg·h/mL >50 μg·h/mL
Study cohort (n = 50) 68 18 14
Simulation (n = 50,000) 42 21 37